Literature DB >> 29629177

Risk factors for progression of and treatment options for NAFLD in children.

Phillipp Hartmann1, Bernd Schnabl2,3.   

Abstract

Entities:  

Keywords:  NAFLD; NASH; non-alcoholic fatty liver disease; pediatric; treatment

Year:  2018        PMID： 29629177      PMCID： PMC5881937          DOI： 10.1002/cld.685

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  11 in total

1.  Prevalence of fatty liver in children and adolescents.

Authors:  Jeffrey B Schwimmer; Reena Deutsch; Tanaz Kahen; Joel E Lavine; Christina Stanley; Cynthia Behling
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

2.  Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents.

Authors:  Antonella Mosca; Valerio Nobili; Rita De Vito; Annalisa Crudele; Eleonora Scorletti; Alberto Villani; Anna Alisi; Christopher D Byrne
Journal:  J Hepatol       Date:  2017-02-14       Impact factor: 25.083

3.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 4.  Interactions between the intestinal microbiome and liver diseases.

Authors:  Bernd Schnabl; David A Brenner
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

5.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

Authors:  Lixin Zhu; Susan S Baker; Chelsea Gill; Wensheng Liu; Razan Alkhouri; Robert D Baker; Steven R Gill
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

6.  Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.

Authors:  Heather M Patton; Katherine Yates; Aynur Unalp-Arida; Cynthia A Behling; Terry T-K Huang; Philip Rosenthal; Arun J Sanyal; Jeffrey B Schwimmer; Joel E Lavine
Journal:  Am J Gastroenterol       Date:  2010-04-06       Impact factor: 10.864

7.  Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity.

Authors:  Jean-Marc Schwarz; Susan M Noworolski; Ayca Erkin-Cakmak; Natalie J Korn; Michael J Wen; Viva W Tai; Grace M Jones; Sergiu P Palii; Moises Velasco-Alin; Karen Pan; Bruce W Patterson; Alejandro Gugliucci; Robert H Lustig; Kathleen Mulligan
Journal:  Gastroenterology       Date:  2017-06-01       Impact factor: 22.682

8.  Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease.

Authors:  Kimberly P Newton; Jiayi Hou; Nancy A Crimmins; Joel E Lavine; Sarah E Barlow; Stavra A Xanthakos; Jonathan Africa; Cynthia Behling; Michele Donithan; Jeanne M Clark; Jeffrey B Schwimmer
Journal:  JAMA Pediatr       Date:  2016-10-03       Impact factor: 16.193

9.  The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease.

Authors:  Phillipp Hartmann; Wei-Chung Chen; Bernd Schnabl
Journal:  Front Physiol       Date:  2012-10-11       Impact factor: 4.566

10.  Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Authors:  Paola Dongiovanni; Quentin M Anstee; Luca Valenti
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116
View more
  10 in total

Review 1.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

Review 2.  Liver cirrhosis and immune dysfunction.

Authors:  Elda Hasa; Phillipp Hartmann; Bernd Schnabl
Journal:  Int Immunol       Date:  2022-09-06       Impact factor: 5.071

3.  New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.

Authors:  Phillipp Hartmann; Bernd Schnabl
Journal:  Semin Liver Dis       Date:  2021-01-14       Impact factor: 6.115

4.  The long-term protective effects of neonatal administration of curcumin against nonalcoholic steatohepatitis in high-fructose-fed adolescent rats.

Authors:  Kasimu G Ibrahim; Eliton Chivandi; Pilani Nkomozepi; Mashudu G Matumba; Emmanuel Mukwevho; Kennedy H Erlwanger
Journal:  Physiol Rep       Date:  2019-03

5.  Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis.

Authors:  Yuli Sun; Zhaofeng Tan; Zhenyuan Jiang; Min Li; Weiqin Wang; Yaoyao Huang; Jianguang Sun
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

6.  Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis.

Authors:  Linghan Kuang; Wei Zhou; Yongmei Jiang
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

7.  Prevalence and risk factors of metabolic-associated fatty liver disease during 2014-2018 from three cities of Liaoning Province: an epidemiological survey.

Authors:  Lin Guan; Xinhe Zhang; Haoyu Tian; Xing Jin; Hang Fan; Ningning Wang; Jing Sun; Dan Li; Jia Li; Xue Wang; Zilu Zeng; Yiling Li
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

8.  Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice.

Authors:  Phillipp Hartmann; Yi Duan; Yukiko Miyamoto; Münevver Demir; Sonja Lang; Elda Hasa; Patrick Stern; Dennis Yamashita; Mary Conrad; Lars Eckmann; Bernd Schnabl
Journal:  Hepatol Int       Date:  2022-01-24       Impact factor: 9.029

9.  Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes.

Authors:  Lucy Gracen; Kelly L Hayward; Melanie Aikebuse; Anthony Russell; James O'Beirne; Steven McPhail; Katharine M Irvine; Suzanne Williams; Patricia C Valery; Elizabeth E Powell
Journal:  BMC Health Serv Res       Date:  2022-04-12       Impact factor: 2.655

10.  Ginkgo biloba Extract 50 (GBE50) Ameliorates Insulin Resistance, Hepatic Steatosis and Liver Injury in High Fat Diet-Fed Mice.

Authors:  Liu Li; Li Yang; Feng Yang; Xin-Lan Zhao; Shengjiang Xue; Fang-Hua Gong
Journal:  J Inflamm Res       Date:  2021-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.